Shuttle Pharmaceuticals Enters into Manufacturing Agreement for Ropidoxuridine
Retrieved on:
Tuesday, September 20, 2022
Radiation, Merck & Co., EPA, Sarcoma, COO, HDAC, Patient, CSO, Brain, Drug development, Research, Contract research organization, Merck, Year, Risk, Coronavirus Scientific Advisory Board (Turkey), Company, Award, International Fertilizer Development Center, Pharmaceutical industry, Glioblastoma, IPO, III, RT, SEC, Pharmacotherapy, American Cancer Society, FDA, CEO, CDMO, Immune system, Cancer, Drug discovery, TCG, Immunotherapy, Survival, Quality of life, API, Medical imaging, Fine chemical, Princeton South Main Street-Courthouse Square Historic District
ROCKVILLE, Md., Sept. 20, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing its side effects, entered into an agreement with TCG GreenChem, Inc. to manufacture Ropidoxuridine, the Company's lead clinical sensitizer drug candidate, for use in formulating the drug product for testing in clinical trials of Ropidoxuridine and RT of cancers.
Key Points:
- "Shuttle Pharma's platform of sensitizers offers a pipeline of product candidates designed to address the urgent clinical need and the current limitations of using 'off-label' drugs with potential new sensitizer agents," said Dr. Anatoly Dritschilo, Chief Executive Officer of Shuttle Pharmaceuticals.
- "Ropidoxuridine, our lead clinical sensitizer drug candidate, sensitizes rapidly growing cancer cells and selective histone deacetylase (HDAC) inhibitors, to sensitize cancer cells and stimulate the immune system.
- For instance, the FDA has already granted approval of our application for orphan-drug designation for Ropidoxuridine for the treatment of glioblastoma.
- Shuttle Pharma will own all intellectual property and improvements developed through the Manufacturing Agreement.